Take Your Trading To The Next Level. Get Started Here!
+1 (949) 514 8188
Biogen said its decision to drop Aduhelm, which had a polarizing approval and launch, was “not related to any safety or efficacy concerns.”
Biogen drops controversial Alzheimer’s drug Aduhelm to focus on Leqembi, experimental treatments
Biogen said its decision to drop Aduhelm, which had a polarizing approval and launch, was “not related to any safety or efficacy concerns.”
Archives
Categories
Archives
Recent Posts
Meta
Categories
Calender